Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial

Abstract

Objective Nonalcoholic fatty liver disease (NAFLD) is a complicated disease and is considered as a severe global health problem affecting 30% of adults worldwide. The present study aimed to evaluate changes in oxidative stress, adipokines, liver enzyme, and body composition following treatment with chromium picolinate (CrPic) among patients with NAFLD. Participants and methods The current randomized, double-blind, placebo-controlled study was conducted on 46 NAFLD patients with the age range of 20–65 years. Patients were randomly classified into two groups, receiving either 400 µg CrPic tablets in two divided doses of 200 µg (23 patients) or placebo (23 patients) daily for 12 weeks. The participants’ body composition and biochemical parameters were evaluated at the baseline and after 12 weeks. Results Serum levels of liver enzymes reduced significantly only in the CrPic group (P < 0.05 for all), but not between the groups after the intervention. Besides, there were significant differences between the study groups regarding body weight and body fat mass, total antioxidant capacity, superoxide dismutase, malondialdehyde, leptin, and adiponectin post-intervention (P = 0.017, P = 0.032, P = 0.003, P = 0.023, P = 0.012, P = 0.003, and P = 0.042, respectively). However, glutathione peroxidase and resistin levels did not differ significantly between groups (P = 0.127 and P = 0.688, respectively). Discussion and conclusion This study showed that consuming 400 µg/day of CrPic for 12 weeks in patients with NAFLD causes a significant change in leptin, adiponectin, oxidative stress (expect glutathione peroxidase), and body weight, compared to baseline. Nevertheless, it does not affect liver enzymes. Therefore, the CrPic supplementation may improve adipokines, some anthropometric indices, and oxidative stress in patients with NAFLD.

Does nano‐curcumin supplementation improve hematological indices in critically ill patients with sepsis? A randomized controlled clinical trial

“…In conformity with our findings, the results of a recent pilot RCT performed by Kooshki et al (2020) showed that there were no meaningful differences in nutritional factors including energy intake and serum levels of albumin and pre‐albumin by nano‐curcumin supplementation. Also, the length of ICU stay did not significantly change between the nano‐curcumin and placebo groups.…”

Efficacy of omega-3-rich Camelina sativa on the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, controlled trial

“…Nonalcoholic fatty liver disease (NAFLD) is a serious and growing medical problem that manifest by the presence of fat in more than 5% of the hepatocytes. NAFLD encompasses a broad spectrum of liver diseases from simple steatosis to nonalcoholic steatohepatitis with further progression to fibrosis, cirrhosis, and hepatocellular carcinoma [1]. The prevalence data reflect that the NAFLD affects about 8–45% of the adult population in the world [2] and currently, prevalence of NAFLD was reported approximately 33.9% in Iran [3].…”

Therapeutic Effects and Mechanisms of Action of Garlic (Allium sativum) on Nonalcoholic Fatty Liver Disease: A Comprehensive Systematic Literature Review

“…e "two-hit" model was revised in 2010 with a "multiple parallel hit" model. In the revised model, fat accumulation in the liver and IR, multiple simultaneous changes lead to an imbalance between antilipotoxic protection systems in the liver and the production of free radicals, endoplasmic stress, decrease in mitochondrial content, disruption of mitochondrial Boxidation, OS, overproduction of reactive nitrogen and oxygen species (RNS/ROS), and death of liver cells [8][9][10]. Even though obesity, especially central obesity, is a wellknown risk factor for NAFLD, it has also been reported in slim people (BMI <30 kg/m2) [11].…”